SWK Holdings Corporation Establishes Record Date for Rights Offering

Dallas, Texas, October 20, 2014 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that it established a record date for its rights offering. Stockholders of record as of October 30, 2014 will be eligible to participate in the rights offering. As part of the rights offering, holders of shares of common stock will receive non-transferable rights to purchase newly issued shares of common stock of the Company. Each subscription right will entitle stockholders to purchase 0.345662431 shares of common stock of the Company at a subscription price of $0.86 per share. If the rights offering is fully subscribed, the Company expects that the gross proceeds from the rights offering will be approximately $12.5 million. The Company intends to use the proceeds from the rights offering for general corporate purposes.

The rights offering will also include an over-subscription privilege that will entitle stockholders who exercise their basic subscription rights in full, the right to purchase additional shares that remain unsubscribed at the expiration of the rights offering, subject to availability and other limitations.

The offering is expected to commence as soon as practicable after the Company’s registration statement becomes effective.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell, or the solicitation of an offer to buy the rights or the underlying shares, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About SWK Holdings Corporation
SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK’s business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. Additional information on the life science finance market is available on the Company’s website at www.swkhold.com.

Statements in this release that are not strictly historical and any statements regarding events or developments that we believe or anticipate will or may occur in the future are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Factors that may cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following: (i) that the Company will not be able to complete the rights offering or that the SEC will not declare the registration statement effective, (ii) that stockholders will not participate in the rights offering and (iii) other factors included in our SEC filings, including our 2013 Annual Report on Form 10-K. These forward looking statements speak only as of the date of this release and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise

CONTACT: SWK Investor Relations at (972) 687-7250 or investor.relations@swkhold.com.